Pluri Inc. (PLUR) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Pluri Inc.
Address
MATAM Advanced Technology Park
Haifa, HA 3508409
Israel
Phone
972 7 4710 8600
Sector
Healthcare
Industry
Biotechnology
Employees
92
First IPO Date
June 30, 2003
Key Executives
| Name | Title | Pay | Year Born |
| Yaacov Yanay | President, Chief Executive Officer & Director | 471,309 | 1971 |
| Liat Zalts | Chief Financial Officer & Treasurer | 267,092 | 1984 |
| Lior Raviv | Chief Technology Officer | 0 | N/A |
| Nimrod Bar Zvi | Chief Commercial Officer | 0 | N/A |
| Ori Shalem | Vice President of Operations & Manufacturing | 0 | N/A |
| Hagit Gal | General Counsel | 0 | 1973 |
| Nofar Glaich-Dabach | Vice President of Human Resources | 0 | N/A |
| Efrat Kaduri | Chief Business Development Officer of Pharma | 0 | N/A |
Description
Pluri Inc., a biotechnology company established in 2001 and headquartered in Haifa, Israel, specializes in developing innovative placenta-derived cell therapies. Its core mission is to tackle a range of inflammatory conditions, muscle injuries, and hematological disorders. The company's therapeutic pipeline centers on placental expanded (PLX) cell technology. A key candidate, PLX-PAD, is in advanced clinical development, with ongoing Phase III trials for muscle recovery after hip fracture surgery, Phase II studies for acute respiratory distress syndrome associated with COVID-19, and Phase I/II trials for steroid-refractory Graft-versus-Host Disease. Additionally, Pluri is advancing PLX-R18, a treatment designed to aid in incomplete hematopoietic recovery following hematopoietic cell transplantation and to address acute radiation syndrome. The company rebranded to Pluri Inc. in July 2022, having previously operated as Pluristem Therapeutics Inc.
